Paradromics, Inc.

Based in Texas, US, Paradromics, Inc. operates as a developer of advanced neurotechnology, focusing on brain-computer interface solutions that enable communication for individuals with severe neurological impairments. Paradromics, Inc. specializes in developing innovative neurotechnology solutions.

Founded in 2015, in Austin, Texas, the company has engaged in 13 investment deals, with its most recent funding round on December 2025, Paradromics, Inc. raised USD 7 million in venture debt funding from new investor Neman Ventures, with participation from returning investor NEOM Investment Fund. The company was co-founded by Andreas Schaefer and Matt Angle, who currently serves as the CEO. Paradromics specializes in advanced neurotechnology, with a focus on its flagship product, the Connexus® Brain-Computer Interface (BCI).

This innovative platform records brain activity at the individual neuron level, utilizing AI algorithms to decode extensive brain data, facilitating the translation of thoughts into actionable treatments. The primary end use cases for this technology include assisting individuals suffering from conditions such as paralysis, movement disorders, chronic pain, addiction, and mental health issues like depression. The Connexus® BCI aims to empower those unable to communicate due to ALS, spinal cord injuries, and strokes, allowing them to interact with digital devices independently. While specific geographical markets for the product are not disclosed, there is an emphasis on targeting regions with significant unmet medical needs, particularly in the United States where the device is currently investigational and not available for sale.

Paradromics' revenue structure is primarily rooted in the commercialization of its proprietary BCI technology, particularly the Connexus® BCI. The company engages in direct-to-consumer transactions, focusing on patients and caregivers who seek innovative solutions for severe communication impairments. The revenue model encompasses partnerships with healthcare institutions, research organizations, and possibly subscription-based services for ongoing support and software updates. The transactional dynamics revolve around the sale or distribution of the Connexus® BCI and associated services, tailored to the specific medical and therapeutic needs of the client base.

As the technology is still in the investigational phase, pricing for these products and services is not publicly defined but is expected to align with industry standards for advanced medical devices. In December 2025, Paradromics, Inc. raised USD 7 million in venture debt funding from new investor Neman Ventures, with participation from returning investor NEOM Investment Fund.